Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Parichehr Malherbe

Roger David Norcross

Raffaello Masciadri

Matthias Heinrich Nettekoven

Emmanuel Pinard

Mark Rogers-Evans

Henner Knust

Olivier Roche

Luca Claudio Gobbi

Eric Prinssen

Hasane Ratni

Andrew William Thomas

The present invention relates to compounds of formula wherein R, R, R, and Rare as defined herein and or to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. These compounds are orexin receptor antagonists and may be useful in the treatment of disorders in which orexin pathways are involved, like sleep disorders.

Heterofused piperidines as orexin antagonists

The present invention relates to compounds of formula I wherein Ar, Ar, Ar, n, andRto Rare as defined herein and to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. These compounds are orexin receptor antagonists and may be useful in the treatment of disorders, in which orexin pathways are involved, like sleep disorders.

Aminoamides as orexin antagonists

The present invention relates to compounds of formula I wherein R, Rand Rare as defined in the specification, which are active at the GABAreceptor and which can be used for the treatment of CNS disorders.

[object Object]

The present invention relates to compounds of formula I wherein Rto Rare as described herein, which compounds are active at the GABAreceptor and can be used for the preparation of medicaments useful in the treatment of CNS disorders comprising anxiety and depression.

The present invention a method of treating anxiety by administering compounds that are active on the GABAreceptor, having formula I: wherein R, R, R, R, Rand Rare as defined in the specification and claims.

2-phenyl-3,3,3-trifluoro-2-hydroxy-propionic acid derivatives

The present invention relates to compounds of formula I wherein

Malonamides as orexin antagonists

The present invention relates to compounds of formula I: wherein R, R, R, R, Rand Rare as defined in the specification and claims, which compounds are active on the GABAreceptor and are useful in the control or prevention of CNS illnesses, especially of illnesses and disorders comprising anxiety, depression, epilepsy, schizophrenia, and cognitive disorders.

The present invention relates to compounds of formula I wherein R, R, R, R, and Rare as defined in the specification. Compounds of the invention are active on the GABAB receptor and are useful for treating a variety of CNS disorders, including anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity-and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, neuropathic pain and craving associated with cocaine and nicotine, psychosis, panic disorder, posttraumatic stress disorders and gastro-intestinal disorders.

Growing community of inventors

Muttenz, Switzerland

Parichehr Malherbe